TREA

90244106 - YIPSCELL

Follow

Information

  • Trademark
  • 90244106
  • Serial Number
    90244106
  • Registration Number
    6747871
  • Filing Date
    October 09, 2020
    5 years ago
  • Registration Date
    May 31, 2022
    3 years ago
  • Transaction Date
    May 31, 2022
    3 years ago
  • Status Date
    May 31, 2022
    3 years ago
  • Published for Opposition Date
    December 14, 2021
    4 years ago
  • Location Date
    April 22, 2022
    3 years ago
  • First Use Anywhere Date
    December 31, 2021
    4 years ago
  • First Use In Commerce Date
    December 31, 2021
    4 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    HUTCHISON, DAVID A
  • Attorney Docket Number
    TUS200045
    Attorney Name
    minchul yang
    Law Office Assigned Location Code
    N50
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
YIPSCELL
Case File Statements
  • GS0051: pharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; biochemical preparations for medical purposes, namely, for the diagnosis and treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; pharmaceutical preparations for the treatment of viral and infectious diseases, autoimmune diseases, kidney diseases, hepatic diseases, neurological diseases and bone diseases; stem cells for medical and veterinary purposes; cultured cells comprised of stem cells for medical use, namely, injection and impanation for treatment of cartilage and meniscus injuries; cells for medical use; cellular function activating agents for medical purposes; cell growth media for growing cells for medical use; reagent kits for medical purposes comprising chemical agents, skin, cartilage and other cells; culture media for cultivating human cells for use in augmentation of bone and other tissues for medical purpose using induced pluripotent cells and embryonic stem-like cells and other stem cells; kit containing chemical media additives being cell growth media for growing cells for medical and veterinary purposes; culture media for cultivating human cells for use in regenerative medicine, oncology, hepatology and hematology; chemical, biochemical, biological, and cell biological products for medical purposes, namely, induced pluripotent stem cells (iPSCs), cell media, cell culture supplements and reagents for cell suspension, cell growth and cell storage; medicines, pharmaceutical products and preparations for health care, namely, induced pluripotent stem cells (iPSCs) and iPSC cultures; cell cultures and cell culture systems for human cells and for medical purposes, namely, induced pluripotent stem cells (iPSCs) and freeze-conserved cells, and reagents for sub cultivation of the cells; intestinal epithelial cell preparations for the treatment of gastrointestinal diseases; pharmaceutical preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; medicinal preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; intestinal epithelial cells for medical purposes; pharmaceutical preparations, namely, live cells in the nature of smooth muscle cells, skeletal muscle cells, myocytes, fibroblasts, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, hepatocytes, organ cells, liver cells, kidney cells, cardiac cells, pancreatic islet cells, cells present in the intestine, stem cells, osteoblasts, cells forming bone or cartilage, hematopoietic cells, parenchymal cells, stroma cells, totipotent cells (iTC), pluripotent cells (iPSC), and progenitor cells (iMSC) for medical purposes; biological implants, namely, live tissue intended for subsequent implantation; pharmaceutical preparations and drug delivery systems comprising chemical agents and stem cells for the treatment of osteoarthritis, cartilage defects, and cartilage injury; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; modified stem cells suitable for use as pharmaceutical biologicals used to regenerate neural and spinal cord tissues in humans
  • PM0001: YIPS CELL
  • GS0421: stem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testing, inspection, research and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, solid state characterization; scientific and technological services, namely, scientific research, development, analysis, testing, and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nanoparticle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; biotechnology research; medical research and development in the field of tissue and cell fabrication; biologic services in the nature of biologic research; biomedical services, namely, laboratory services for human tissue, blood, blood components and stem cells for medical use; medical and scientific laboratory services, namely, development of induced pluripotent stem cells using cells derived from healthy and ill humans; medical and scientific laboratory services, namely, development of induced pluripotent stem cell lines using customized primary cells; medical and scientific laboratory services, namely, evaluating of drugs capable of differentiating various serovars suitable for diseases using induced pluripotent stem cells; medical and scientific laboratory services, namely, evaluating of drug efficacy for technology for making animal models of various diseases; medical and scientific laboratory services, namely, evaluating of the quality of induced pluripotent stem cells; medical services, namely, research services relating to stem cells; research, development and testing services for others in the fields of genomics, biotechnology, chemistry and pharmaceuticals; conducting clinical trials for others in the field of stem cell based therapies and products; scientific research services, namely, tracking, analyzing, forecasting, and reporting data in the field of clinical trials of stem cell based therapies and products
Case File Event Statements
  • 5/31/2022 - 3 years ago
    41 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 5/31/2022 - 3 years ago
    40 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 4/23/2022 - 3 years ago
    39 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA
  • 4/22/2022 - 3 years ago
    38 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR
  • 4/22/2022 - 3 years ago
    37 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC
  • 4/11/2022 - 4 years ago
    36 - USE AMENDMENT FILED Type: IUAF
  • 4/22/2022 - 3 years ago
    35 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 4/11/2022 - 4 years ago
    34 - TEAS STATEMENT OF USE RECEIVED Type: EISU
  • 2/8/2022 - 4 years ago
    33 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 12/14/2021 - 4 years ago
    32 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/14/2021 - 4 years ago
    31 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/24/2021 - 4 years ago
    30 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/9/2021 - 4 years ago
    29 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/8/2021 - 4 years ago
    28 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 11/8/2021 - 4 years ago
    27 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 11/8/2021 - 4 years ago
    26 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 11/8/2021 - 4 years ago
    25 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 11/5/2021 - 4 years ago
    24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/4/2021 - 4 years ago
    23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/4/2021 - 4 years ago
    22 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/23/2021 - 4 years ago
    21 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/23/2021 - 4 years ago
    20 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/23/2021 - 4 years ago
    19 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 10/19/2021 - 4 years ago
    18 - PREVIOUS ALLOWANCE COUNT WITHDRAWN Type: ZZZX
  • 10/12/2021 - 4 years ago
    17 - WITHDRAWN FROM PUB - OG REVIEW QUERY Type: PBCR
  • 9/27/2021 - 4 years ago
    16 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/24/2021 - 4 years ago
    15 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 9/24/2021 - 4 years ago
    14 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 9/24/2021 - 4 years ago
    13 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 8/4/2021 - 4 years ago
    12 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 8/4/2021 - 4 years ago
    11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 8/4/2021 - 4 years ago
    10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 7/28/2021 - 4 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/28/2021 - 4 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/28/2021 - 4 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/1/2021 - 5 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/1/2021 - 5 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/1/2021 - 5 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/9/2021 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/24/2020 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 10/13/2020 - 5 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP